Cells producing recombinant retrovirus with thymidine kinase gene from Herpes simplex virus suitable for human cancer gene therapy

Neoplasma

Volumn 46, Issue 6, 1999, Pages 329-334

  Hlavaty J ^a   Hlubinova K ^a   Bies, J ^a   Altaner, C ^a  

^a INSTITUTE OF CHEMISTRY   (Slovakia)

Author keywords

Gene therapy; HSVtk; Retrovital vector producing cells

Indexed keywords

GANCICLOVIR; THYMIDINE KINASE;

ANIMAL CELL; ARTICLE; CELL CLONING; CELL DIVISION; CONTROLLED STUDY; GENE EXPRESSION; GENE THERAPY; GENETIC TRANSDUCTION; HERPES SIMPLEX; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; RAT; VIRUS REPLICATION;

EID: 0033379437     PISSN: 00282685     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. BASSIN, R.H., RUSCETTI, S., ALI, I., HAAPALA, D.K., REIN,A.: Normal DBA/2 mouse cells synthesize a glycoprotein which interferes with MCF virus infection. Virology, 123, 1982, 139-151.
2. BI, W.L., PARYSEK, L.K., WARNICK, R., STAMBROOK, P.J.: In vitro evidence that metabolic cooperation is responsible for the bystander effect observed with HSV TK retroviral gene therapy. Hum. Gene Ther., 4, 1993, 725-731.
3. BORDIGNON, C., BONINI, C., VERZELETTI, S., NOBILI, N., MAGGIONI, D., TRAVERSARI, C., GIAVAZZI, R., SERVIDA, P., ZAPPONE, E., BENAZZI, E., BERNARDI, M., PORTA, F., FERRARI, G., MAVILIO, F., ROSSINI, S., BLAESE, R.M., CANDOTTI, F.: Transfer of the HSV-tk gene into donor peripheral blood lymphocytes for in vivo modulation of donor anti-tumor immunity after allogenic bone marrow transplantation. Hum. Gene Ther., 6, 1995, 813-819.
4. COLOMBO, B.M., BENEDETTI, S., OTTOLENGHI, S., MORA, M., POLLO, B., POLI, G., FINOCCHIARO, G.: The "bystander effect": Association of U-87 cell death with ganciclovir-mediated apoptosis of nearby cells and lack of effect in athymic mice. Hum. Gene Ther., 6, 1995, 763-772.
5. COOPER, D., PENNY, R., SYMONDDS, G., CARR, A., GERLACH, W., SUN, L.Q., ELY, J.: A marker study of therapeutically transduced CD4+ peripheral blood lymphocytes in HIV discordant identical twins. Hum. Gene Ther., 10, 1999, 1401-1421.
6. CORNETTA, K., MOEN, R.C., CULVER, K., MORGAN, R.A., MCLACHLIN, J.R., STURM, S., SELEGUE, J., LONDON, W., BLAESE, R.M., ANDERSON, W.F.: Amphotropic murine leukemia retrovirus is not an acute pathogen for primates. Hum. Gene Ther., 1, 1990, 15-30.
7. CORNETTA, K., MORGAN, R.A., GILLI, A., STRURM, S., BALTRUCKI, L., O'REILLY, R., ANDERSON, W.F.: No retroviremia or pathology in long-term follow-up of monkeys exposed to a murine amhotropic retrovirus. Hum. Gene Ther., 2, 1991, 215-219.
8. DONAHUE, R.E., KESSLER, S.W., BODINE, D., MCDONAGH, K., DUNBAR, C., GOODMAN, S., AGRICOLA, B., BYRNE, E., RAFFELD, M., MOEN, R., BACHER, J., ZSEBO, K.M., NIENHUIS, A.W.: Helper virus induced T cell lymphoma in non-human primates after retroviral mediated gene transfer. J. Exp. Med., 176, 1992, 1125-1135.
9. FREEMAN, S.M., ABBOUD, C.N., WHARTENBY, K.A., PACKMAN, C.H., KOEPLIN, D.S., MOOLTEN, F.L., ABRAHAM, G.N.: The "bystander effect": Tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res., 53, 1993, 5274-5283.
10. FREEMAN, S.M., RAMESH, R., MARROGI, A.J.: Immune system in suicide gene therapy. Lancet, 349, 1997, 2-3.
11. GAGENDEEP, S., BREW, R., GREEN, B., CHRISTMAS, S.E., KLATZMANN, D., POSTON, G.J., KINSELLA, A.R.: Prodrug-activated gene therapy: Involvement of an immunological component in the "bystander effect". Cancer Gene Ther., 3, 1996, 83-88.
12. HALL, S.J., SANFORD, M.A., ATKINSON, G., CHEN, S.H.: Induction of potent antitumor natural killer cell activity by Herpes simplex virus-thymidine kinase and ganciclovir therapy in an orthotopic mouse model of prostate cancer. Cancer Res., 58, 1998, 3221-3225.
13. HLAVATÝ, J., HLUBINOVÁ, K., ALTANEROVÁ, V., LIŠKA, J., ALTANER, Č.: Treatment of rat gliomas with recombinant retrovirus harboring Herpes simplex virus thymidine kinase suicide gene. Neoplasma, 44, 1997, 342-347.
14. KLATZMANN, D., PHILIPPON, J., VALERY, C.A., BENSIMON, G., SALZMANN, J.L. and the Study Group on Gene Therapy for Glioblastoma: Gene therapy for glioblastoma in adult patients: Safety and efficacy evaluation of an in situ injection of recombinant retrovirus-producing cells carrying the thymidine kinase gene of the Herpes simplex type 1 virus, to be followed with the administration of ganciclovir. Hum. Gene Ther., 7, 1996, 109-126.
15. KLATZMANN, D., CHERIN, P., BENSIMON, G., BOYER, O.,COUTELLIER, A., CHARLOTTE, F., BOCCACCIO, C., SALZMANN, J.L., HERSON, S. and the Study Group on Gene Therapy of Metastatic Melanoma: A phase I/II Dose-escalation study of Herpes simplex virus type 1 thymidine kinase "suicide" gene therapy for metastatic melanoma. Hum. Gene Ther., 9, 1998, 2585-2594.
16. KLATZMANN, D., VALERY, C.A., BENSIMON, G., MARRO, B., BOYER, O., MOKHTARI, K., DIQUET, B., SALZMANN, J.L., PHILIPPON, J. and the Study Group on Gene Therapy for Glioblastoma: A phase I/II study of Herpes simplex virus type 1 thymidine kinase "suicide" gene therapy for recurrent glioblastoma. Hum. Gene Ther., 9, 1998, 2595-2604.
17. LANDER, M.R., CHATTOPADHYAY, S.K.: A M. dunni cell line that lacks sequences closely related to endogenous murine leukemia viruses and can be infected by ecotropic, amphotropic, xenotropic, and mink cell focus-forming viruses. J. Virol., 52, 1984, 695-698.
18. LINK, C.J., MOORMAN, D., SEREGINA, T., LEVY, J.P., SCHABOLD, K.J.: A phase I trial of in vivo gene therapy with the Herpes simplex thymidine kinase/ganciclovir system for the treatment of refractory or recurrent ovarian cancer. Hum. Gene Ther., 7, 1996, 1161-1179.
19. LONG, Z., LI, L.-P., GROOMS, T., LOCKEY, C., NADER, K.L., MYCHKOVSKY, I., MUELLER, S., BURIMSKI, I., RYAN, P., KIKUCHI, G., ENNIST, D., MARCUS, S., OTTO, E., MC GARRITY, G.J.: Biosafety monitoring of patients receiving intracerebral injections of murine retroviral vector producer cells. Hum. Gene Ther., 9, 1998, 1165-1172.
20. MC MASTERS, R., SAYLORS, R.L., JONES, K.E., HENDRIX, M.E., MOYER, M.P., DRAKE, R.: Lack of bystander killing in Herpes simplex virus thymidine kinase-transduced colon cell lines due to deficient connexin 43 gap junction formation. Hum. Gene Ther., 9, 1998, 2253-2261.
21. MILLER, A.D., LAW, M.-F., VERMA, I.: Generation of helper-free amphotropic retroviruses that transduce a dominant-acting, methotrexate-resistant dihydrofolate reductase gene. Moll. Cell Biol., 5, 1985, 431-437.
22. MILLER, A.D., BUTTIMORE, C.: Redesign of retrovirus packaging cell lines to avoid recombination leading to helper virus production. Mol. Cell. Biol., 6, 1986, 2859-2902.
23. OLDFIELD, E.H., RAM, Z., CHIANG, Y., BLAESE, R.M.: Intrathecal gene therapy for the treatment of leptomeningeal carcinomatosis. Hum. Gene Ther., 6, 1995, 55-85.
24. OTTO, E., JONES-TROWER, A., VANIN, E. F., STAMBAUGH, K., MUELLER, S.N., ANDERSON, W.F., MC GARRITY, G.J.: Characterization of replication-competent retrovirus resulting from recombination of packaging and vector sequences. Hum. Gene Ther., 5, 1994, 567-575.
25. PRINCEN, F., LECHANTEUR, C., LOPEZ, M., ROCOUX, G., DEETROZ, B., GIELEN, J., FILLET, G., MERVILLE, M.-P., BOURS, V.: Repeated cycles of retrovirus-mediated HSVtk gene transfer plus ganciclovir increase survival of rats with peritoneal carcinomatosis. Gene Ther., 5, 1998, 1054-1060.
26. PRINTZ, M., REYNOLDS, J., MENTO, S.J., JOLLY, D., KOWAL, K., SAJJADI, N.: Recombinant retroviral vector interferes with the detection of amphotropic replication competent retrovirus in standard culture assays. Gene Ther., 2, 1995, 143-150.
27. RAM, Z., CULVER, K.W., OSHIRO, E.M., VIOLA, J.J., DE VROOM, H.L., OTTO, E., LONG, Z., CHIANG, Y., MC GARITTY, G.J., MUUL, L.M., KATZ, DD., BLAESE, R.M., OLDFIELD, E.H.: Therapy of malignant brain tumors by intratumoral implantation of retroviral vector-producing cells. Nat. Med., 3, 1997, 1354-1361.
28. SHORT, M.P., CHOI, B.C., LEE, J.K., MALICK, A., BREAKEFIELD, X.O., MARTUZA, R.L.: Gene delivery to glioma cells in rat brain by grafting of a retrovirus packaging cell line. J. Neurosci. Res., 27, 1990, 427-439.
29. VRIONIS, F.D., WU, J.K., QI, P., WALTZMAN, M., CHERINGTON, V., SPRAY, D.D.: The bystander effect exerted by tumor cells expressing the Herpes simplex virus thymidine kinase (HSVtk) gene is dependent on connexin expression and cell communication via gap junctions. Gene Ther., 4, 1997, 577-585.
30. WILSON, C.A., NG, T.-H., MILLER, A.E.: Evaluation of recommendations for replication-competent retrovirus testing associated with use of retroviral vectors. Hum. Gene Ther., 8, 1997, 869-874.